Skip to main content

Table 1 Demographic data.

From: Free-living gait characteristics in ageing and Parkinson’s disease: impact of environment and ambulatory bout length

Characteristic

CL (n = 50) Mean (SD)

PD (n = 47) Mean (SD)

p

Male/female (n)

m 27, f 23

m 34, f 13

0.062

Age (years)

69.8 (7.2)

69.1 (8.3)

0.694

MMSE (0 - 30)

28.4 (1.7)

28.3 (2.0)

0.827

MoCA (0 - 30)+

27.6 (2.4)

26.0 (3.8)

0.016

GDS (0 - 15)

1.0 (1.5)

2.7 (2.7)

<0.001

MFI Total fatigue (20 - 100)

34.7 (13.2)

49.9 (18.6)

<0.001

ABCs (0 - 100 %)

91.7 (11.0)

80.4 (18.4)

0.001

Hoehn & Yahr stage (n)

-

HY I 5

-

HY II 39

HY III 3

Levodopa Equivalent Daily Dose

-

419.6 (214.0)

-

MDS-UPDRS III

-

32.0 (10.1)

-

Freezing of gait (n, %)

-

7 (14.9 %)

-

Motor Phenotype (n)

-

PIGD 18

-

ID 6

TD 23

  1. MMSE mini mental state exam, MoCA montreal cognitive assessment, GDS geriatric depression scale, MFI multidimensional fatigue inventory, ABCs activities specific balance confidence scale, UPDRS Unified Parkinson’s disease rating scale, PIGD postural instability and gait disorder phenotype, ID indeterminate phenotype, TD tremor dominant phenotype. p difference between CL and people with PD. In bold significant p values (p < 0.05)
  2. Clinical and demographic characteristics for control participants (CL), and people with Parkinson’s disease (PD). In bold are shown significant p values < 0.05